Me Again Meds

Me Again Meds predicts antidepressant remission probabilities from OptumLabs claims data to support personalized antidepressant selection across comorbidities, demographics, and prescription patterns.

Key Features:

• Data-Driven Insights: Uses OptumLabs claims data from 3,678,082 patients with major depression (January 2001–December 2018) encompassing over 10 million antidepressant treatments.
• Subgroup Analysis: Identifies 16,770 patient subgroups based on predictors of remission and prescription patterns.
• Remission Rate Evaluation: Quantifies variability in remission rates across strata, with the best-performing antidepressant in certain subgroups reaching a 50.78% remission rate.
• Statistical Validation: Predictive models of clinicians' prescription patterns achieved a cross-validated AROC of 82.0% and patient remission prediction achieved a cross-validated AROC of 72.0%.
• Personalized Recommendations: Matches individual patient medical history to similar cases in the dataset and recommends antidepressants based on observed subgroup remission rates.
• Heterogeneity Testing: Applies the Breslow-Day chi-square test to confirm heterogeneity of antidepressant efficacy across different strata.

Scientific Applications:

• Personalized Medicine: Refines antidepressant selection by accounting for individual patient characteristics and comorbidities.
• Clinical Decision Support: Provides evidence-based recommendations to support clinicians in optimizing treatment strategies for major depression.
• Research Insights: Characterizes variability of antidepressant efficacy across patient subgroups to inform personalized pharmacotherapy research.

Methodology:

Retrospective observational matched case-control study using OptumLabs claims data; identification of 16,770 subgroups based on predictors of remission and prescription patterns; predictive models evaluated with cross-validation producing reported AROC values; heterogeneity assessed with the Breslow-Day chi-square test.